Transcriptomic Analysis Reveals the Protection of Astragaloside IV against Diabetic Nephropathy by Modulating Inflammation
Joint Authors
Zhang, Yudi
Tao, Chunhe
Xuan, Chen
Jiang, Junyan
Cao, Wenfu
Source
Oxidative Medicine and Cellular Longevity
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-17, 17 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-08-14
Country of Publication
Egypt
No. of Pages
17
Main Subjects
Abstract EN
Background.
Diabetic nephropathy (DN) is one of the leading causes of end-stage kidney disease.
Recently, there is no specific drug available to block the kidney damage.
Astragaloside IV (AS-IV) is a major active component of Astragalus membranaceus (Fisch) Bge and has been demonstrated to benefit the kidney functions.
This study explores the potential pharmacological action of AS-IV in DN of rats.
Methods.
Male Sprague-Dawley rats were fed with high-fat diet and injected with streptozotocin to induce diabetes.
The diabetic rats were randomized and treated with vehicle or AS-IV (80 mg/kg) daily by gavage for 12 weeks as the DN or AS-IV group, respectively.
The normal control rats were fed with normal chow and injected with vehicles (n=8 per group).
These rats were monitored for diabetes- and kidney function-related measures.
The expression profiles of gene mRNA transcripts in the kidney tissues were analyzed by RNA-seq and quantitative RT-PCR.
The levels of advanced glycation end products (AGEs), IL-1β, and IL-18 in the serum samples and kidney tissues were quantified by ELISA.
The levels of collagen IV (COL-4) and fibronectin (FN) expression in kidney tissues were examined by immunohistochemistry and Western blot.
Results.
In comparison with the DN group, AS-IV treatment significantly reduced blood glucose levels, food and water consumption, 24 h urine, renal index values, 24 h urine total proteins, blood urea nitrogen (BUN) levels, and creatinine clearance rates (CCR), accompanied by minimizing the DN-induced early kidney damages, fibrosis, and microstructural changes.
Furthermore, AS-IV treatment significantly modulated the DN-altered gene transcription profiles in the kidney of rats, particularly for inflammation-related genes, including the nucleotide-binding oligomerization domain-like receptor signaling, which was validated by quantitative RT-PCR.
AS-IV treatment significantly decreased the levels of serum and kidney AGEs, IL-1β, and IL-18 expression and fibrosis indexes in the kidney of rats.
Conclusion.
AS-IV treatment ameliorated the severity of DN by inhibiting inflammation-related gene expression in the kidney of rats.
American Psychological Association (APA)
Zhang, Yudi& Tao, Chunhe& Xuan, Chen& Jiang, Junyan& Cao, Wenfu. 2020. Transcriptomic Analysis Reveals the Protection of Astragaloside IV against Diabetic Nephropathy by Modulating Inflammation. Oxidative Medicine and Cellular Longevity،Vol. 2020, no. 2020, pp.1-17.
https://search.emarefa.net/detail/BIM-1206080
Modern Language Association (MLA)
Zhang, Yudi…[et al.]. Transcriptomic Analysis Reveals the Protection of Astragaloside IV against Diabetic Nephropathy by Modulating Inflammation. Oxidative Medicine and Cellular Longevity No. 2020 (2020), pp.1-17.
https://search.emarefa.net/detail/BIM-1206080
American Medical Association (AMA)
Zhang, Yudi& Tao, Chunhe& Xuan, Chen& Jiang, Junyan& Cao, Wenfu. Transcriptomic Analysis Reveals the Protection of Astragaloside IV against Diabetic Nephropathy by Modulating Inflammation. Oxidative Medicine and Cellular Longevity. 2020. Vol. 2020, no. 2020, pp.1-17.
https://search.emarefa.net/detail/BIM-1206080
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1206080